Peter Ordentlich
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Molecular Biology top 2%
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Developmental Biology and Gene Regulation
- Protein Degradation and Inhibitors
- Retinoids in leukemia and cellular processes
Papers in
-
- Histone Deacetylase Inhibitors Research 42
- Protein Degradation and Inhibitors 18
- Retinoids in leukemia and cellular processes 8
- Epigenetics and DNA Methylation 8
- Oncology 23
- Cancer Immunotherapy and Biomarkers 13
- Co-authors
- Ronald M. Evans (7 shared papers)Michael Downes (6 shared papers)Hung‐Ying Kao (5 shared papers)Tom Kadesch (5 shared papers)Richard A. Heyman (4 shared papers)Yingzhuo Yan (2 shared papers)Zhenyu Tang (1 shared paper)Chris Kintner (1 shared paper)
- Journals
- Cancer Research (19 papers)Journal of Clinical Oncology (11 papers)Clinical Cancer Research (4 papers)Genes & Development (4 papers)Blood (4 papers)
- Partner nations
- United StatesAustraliaSouth Africa
In The Last Decade
Peter Ordentlich
66 papers receiving 4.2k citations
Peers
Comparison fields: 5 of 109
- Oncology 1.2k
- Molecular Biology 2.9k
- Immunology 806
- Cellular and Molecular Neuroscience 500
- Genetics 725
Countries citing papers authored by Peter Ordentlich
This map shows the geographic impact of Peter Ordentlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ordentlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ordentlich more than expected).
Fields of papers citing papers by Peter Ordentlich
This network shows the impact of papers produced by Peter Ordentlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ordentlich. The network helps show where Peter Ordentlich may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Ordentlich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 67 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1998 | 477 | |
| 2 | 2002 | 437 | |
| 3 | 2000 | 350 | |
| 4 | 2017 | 291 | |
| 5 | 2001 | 266 | |
| 6 | 1998 | 224 | |
| 7 | 2008 | 220 | |
| 8 | 1998 | 165 | |
| 9 | 2004 | 159 | |
| 10 | 1999 | 146 | |
| 11 | 2004 | 141 | |
| 12 | 2003 | 126 | |
| 13 | 2000 | 121 | |
| 14 | 2003 | 109 | |
| 15 | 2003 | 89 | |
| 16 | 2020 | 83 | |
| 17 | 2001 | 67 | |
| 18 | 2016 | 58 | |
| 19 | 2009 | 56 | |
| 20 | 1997 | 46 |
About Peter Ordentlich
Peter Ordentlich is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Immunology and Genetics, having authored 67 papers that have together received 4.2k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (42 papers), Protein Degradation and Inhibitors (18 papers), Cancer Immunotherapy and Biomarkers (13 papers), Advanced Breast Cancer Therapies (10 papers), Retinoids in leukemia and cellular processes (8 papers), Epigenetics and DNA Methylation (8 papers), Estrogen and related hormone effects (7 papers) and Immune cells in cancer (4 papers). The work is most often cited by research in Oncology (1.2k citations), Molecular Biology (2.9k citations), Immunology (806 citations), Cellular and Molecular Neuroscience (500 citations) and Genetics (725 citations). Peter Ordentlich has collaborated with scholars based in United States, Australia and South Africa. Frequent co-authors include Ronald M. Evans, Michael Downes, Hung‐Ying Kao, Tom Kadesch, Richard A. Heyman, Yingzhuo Yan, Zhenyu Tang, Chris Kintner, Naoko Koyano‐Nakagawa and Wen Xie. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research, Genes & Development and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.